SURVYR

RCUS

Arcus Biosciences, Inc.
$18.39
+$0.25 (1.38%)Oct 28 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-12%+9%+29%+50%+71%Oct 2025Oct 2026Apr 202652w high $31.7352w low $16.41
RCUSSPY
Wall St. Highest PT $50.00 (+171.9%) Wall St. Avg PT $41.31 (+124.6%)
$18$30$42$54$66POC $24Hi $50Avg $41
Underwater Drawdown %Max DD -43.7%Current -41.7%
0.0%-43.7%
Relative Strength vs SPY-15.1% vs SPYUnderperforming
+68%0%-68%
1W
−$5.36 (22.57%)
1M
−$6.62 (26.47%)
3M
−$8.06 (30.47%)
6M
−$5.74 (23.79%)
YTD
−$5.44 (22.83%)
1Y
−$1.49 (7.49%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
13 analysts · mean score 1.33
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$18.39
Average target$41.31
+$22.92 (+124.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$23.00
Median$41.31
High$50.00
12-month Wall Street target range
Recent analyst rating changes · 8
Initiated
2026-10-16 · William Blair started covering RCUS at Outperform
Initiated
2026-10-14 · JP Morgan started covering RCUS at Overweight
Reiterated
2026-09-30 · Wedbush reiterated Outperform on RCUS
Initiated
2026-09-16 · TD Cowen started covering RCUS at Buy
Reiterated
2026-09-08 · Truist Securities reiterated Buy on RCUS
Reiterated
2026-08-06 · Wells Fargo reiterated Equal-Weight on RCUS
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$3.0B
P/E (next 12 months, estimated)-7.6
52-week range$16.41 – $31.73
Revenue growth (latest quarter vs a year ago)-74.4%
Dividend yieldNo dividend
Analyst consensusStrong Buy (13)
Average analyst price target$41.31 (+125%)

What they do

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
66th percentile in sector
B
12-1 return: +31.0%
Percentile within its GICS sector across the S&P 1500.
Growth
1st percentile in sector
F
Revenue growth (YoY): -74.4%
Percentile within its GICS sector across the S&P 1500.
Value
Not enough data yet
–
Forward E/P: – · EBITDA/EV: –
Percentile within its GICS sector across the S&P 1500.
Profitability
12th percentile in sector
D-
Profit margin: +0.0% · Return on equity: -90.8%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

RCUS earningsNext report in -1 days
Next report
Tue Oct 27, 2026Time not confirmed
EPS consensus-$0.89 range -$1.00–-$0.84
Revenue consensus$9.5M 11 analysts
Last 4 quarters · EPS vs estimate
Aug 5, 2026-$0.72est -$0.81+11.6%Above estimates
May 5, 2026-$1.02est -$0.83−23.3%Below estimates
Feb 25, 2026-$0.89est -$1.07+17.2%Above estimates
Oct 28, 2025-$1.27est -$1.29+1.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 01:31:43 ET
24-0824-1125-0225-0525-1026-0226-0526-08-1.390.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$41.0M-74.4%
2026-03-31$17.0M–
2025-12-31$33.0M–
2025-09-30$26.0M–
2025-06-30$160.0M–

News & catalysts

More news
Arcus Biosciences, Inc. (RCUS) files 8-K: other event
SEC 8-K · Oct 23
Arcus Biosciences stock falls on public offering announcement
Investing.com · Oct 21
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
PR Newswire · Oct 21
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Business Wire · Oct 21
Why is Arcus Biosciences stock sliding today?
Investing.com · Oct 20
Rating changes
Initiated
2026-10-16 · William Blair started covering RCUS at Outperform
Initiated
2026-10-14 · JP Morgan started covering RCUS at Overweight
Reiterated
2026-09-30 · Wedbush reiterated Outperform on RCUS
Initiated
2026-09-16 · TD Cowen started covering RCUS at Buy
Reiterated
2026-09-08 · Truist Securities reiterated Buy on RCUS
Reiterated
2026-08-06 · Wells Fargo reiterated Equal-Weight on RCUS

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Azoy Alexander
Chief Accounting Officer · 2026-08-21
Sell
$84.8K

Stats refreshed 2026-10-21 01:31:43 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026